# US 2016/0152667 A1 · Compositions and methods for the treatment of viral infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0152667 A1
- Document ID: US20160152667A1
- Status: Published application
- Kind: A1
- Application number: 15/019,558
- Filed: 2016-02-09
- Published: 2016-06-02
- Earliest claimed: 2008-01-23
- Assignees: Dana-Farber Cancer Institute, Inc.
- Applicants: Dana-Farber Cancer Institute, Inc.
- Inventors: Loren D. Walensky; Gregory H. Bird
- Web page: https://patentgrep.com/patent/US20160152667A1

## CPC

- C07K 14/005: from viruses
- A61K 38/162: {from virus}
- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61K 39/155: Paramyxoviridae, e.g. parainfluenza virus
- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/18: for HIV
- C07K 16/1145: {Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12N 2740/15022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/15034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/15071: Demonstrated in vivo effect
- C12N 2740/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16171: Demonstrated in vivo effect
- C12N 2740/16222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/16234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16271: Demonstrated in vivo effect
- C12N 2760/14022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/14034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/14071: Demonstrated in vivo effect
- C12N 2760/16022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16071: Demonstrated in vivo effect
- C12N 2760/18022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/18034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/18071: Demonstrated in vivo effect
- C12N 2760/18522: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/18534: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/18571: Demonstrated in vivo effect
- C12N 2760/18622: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/18634: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/18671: Demonstrated in vivo effect
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention provides compositions, kits and methods utilizing polypeptides having a viral alpha-helix heptad repeat domain in a stabilized α-helical structure (herein also referred to as SAH). The compositions are useful for treating and/or preventing viral infections. The invention is based, at least in part, on the result provided herein demonstrating that viral hydrocarbon stapled alpha helical peptides display excellent proteolytic, acid, and thermal stability, restore the native alpha-helical structure of the peptide, are highly effective in interfering with the viral fusogenic process, and possess superior pharmacokinetic properties compared to the corresponding unmodified peptides.

## Claims

### Claim 1

A modified polypeptide comprising a stabilized alpha helix of HIV gp41 heptad repeat domain.

### Claim at position 2

-61. (canceled)

### Claim 62

A method for inhibiting transmission of HIV to a cell comprising contacting the virus in the presence of the cell with an effective dose of a modified polypeptide comprising a stabilized alpha helix of HIV gp41 heptad repeat domain, so that the infection of the cell by the virus is inhibited.

### Claim at position 4

-70. (canceled)

### Claim 71

A method for treating or delaying the onset of AIDS in an HIV infected individual, comprising administering to the individual an effective dose of a pharmaceutical composition comprising a modified polypeptide comprising a stabilized alpha helix of HIV gp41 heptad repeat domain.

### Claim at position 6

-85. (canceled)